Results from Novo Nordisk, presented at ObesityWeek ® , showed treatment with semaglutide injection 2.4 mg resulted in significant reductions in hospital admissions as well as overall time spent in the hospital 1 Cardiovascular disease represents the leading cause of death globally, 2 and adults with obesity are at a higher risk of developing cardiovascular disease 3 The analysis is based on SELECT, a large cardiovascular outcomes trial that evaluated the effect of semaglutide 2.4 mg on the risk of MACE (heart attack, stroke, or death) in adults with overweight or obesity and known heart disease 4 PLAINSBORO, N.
J. , Nov. 3, 2024 /PRNewswire/ -- Today, Novo Nordisk presented an exploratory post hoc analysis from the SELECT phase 3 cardiovascular outcomes trial that showed semaglutide 2.
4 mg significantly reduced hospital admissions and overall length of hospital stay for adults with obesity or overweight with established cardiovascular disease (CVD) and without diabetes. 1 The results were presented during an oral session at the annual ObesityWeek ® conference and provide further insights based on data from SELECT– a large cardiovascular outcomes trial that evaluated the effect of semaglutide 2.4 mg on the risk of MACE (heart attack, stroke, or death) in this population.
CVD covers a wide range of conditions that, when combined, represent the leading cause of death globally and are associated with substantial healthcare costs. 2,5 Obesity directly increases the risk of CVD.
